Psoriasis and atopic dermatitis, the two most studied inflammatory skin diseases, reprogram immune metabolism in opposite directions. That is the central claim of a new review published in Frontiers, titled "Divergent immunometabolic reprogramming in psoriasis and atopic dermatitis: a tale of two inflammatory skin diseases."

The premise is simple. Two diseases. Same organ. Different metabolic engines.

For decades, clinicians have grouped psoriasis and atopic dermatitis under the broad umbrella of chronic inflammatory dermatoses. Both involve keratinocyte dysfunction, immune dysregulation and a disrupted skin barrier. But the review argues that at the metabolic level — how immune cells burn fuel and build inflammatory molecules — the diseases part ways.

Why does immunometabolism matter?

Immunometabolism is the study of how cellular metabolism shapes immune behavior. A T cell that burns glucose one way may promote inflammation. The same cell, rewired, may calm it.

In psoriasis, the review frames the disease around the IL-23/IL-17 axis, with Th17 cells as the dominant inflammatory drivers. In atopic dermatitis, the spotlight falls on Th2 cytokines such as IL-4 and IL-13, acting on a type 2 inflammatory background.

These immune profiles are already well established in the literature. What the review adds is the argument that each profile carries its own metabolic fingerprint — its own "reprogramming" — and that the divergence matters therapeutically.

What does "divergent reprogramming" mean?

The word "tale" in the title is deliberate. The authors present the two diseases as parallel stories that split at a metabolic fork.

In psoriasis, the inflammatory milieu favors pathways that support Th17 effector function. In atopic dermatitis, the metabolic setup sustains Th2-skewed inflammation. The review draws on published evidence to contrast these settings rather than treat chronic skin inflammation as one metabolic entity.

The takeaway in plain words: drugs that target metabolism in one disease may not translate to the other, because the underlying metabolic wiring differs.

Why should clinicians care?

The clinical stakes are concrete. Psoriasis and atopic dermatitis already respond to different biologic classes — IL-17 and IL-23 inhibitors on one side, IL-4 receptor blockade with dupilumab on the other. A metabolic explanation for that divergence could sharpen how researchers design the next generation of therapies.

The review also situates itself in a growing field. Immunometabolism has moved from basic immunology into dermatology over the past decade, with increasing attention to how nutrients, metabolites and cellular energy pathways regulate skin inflammation.

What comes next?

By framing psoriasis and atopic dermatitis as metabolically distinct diseases, the authors set an agenda: future work should test whether metabolic targets can be matched to each condition individually, opening a path toward metabolism-informed therapy choices in inflammatory skin disease.